Remove 2007 Remove Testimonials Remove Treatment
article thumbnail

Fatty Liver Case Study cb | Blue Heron Health News

The Pharma Data

No treatments? According to the Centre for Disease Control and Prevention, the number of deaths caused by liver disease and cirrhosis has risen every year since 2007. I would examine my options for treatments in case my fatty liver became even fattier. That there are no ‘anti-fatty liver’ meds? No procedures?

Doctors 52
article thumbnail

Let's Quit Sugar With Audiobook – Let's Quit Sugar

The Pharma Data

You should not use the information on this site for diagnosis or treatment of any health problem or for prescription of any medication or other treatment. Testimonials are not necessarily representative of all of those who will use our products. 2007 Nov;86(5):1354- 63. 2007 Oct;15(5):481-91. All Rights Reserved.

Disease 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Package | Prasara Yoga

The Pharma Data

Nothing accessed is to be interpreted as a general or specific recommendation for a specific treatment plan, product, exercise regimen or course of action. individual ailment, treatment or problem. 1 Best Fitness System of 2008 by Cleo Magazine, and “Most Challenging Workout of 2007? All testimonials on this site are real.

article thumbnail

Malarkey ? The Ten Worst Prescription Drug/Medical Device Decisions of 2023

Drug & Device Law

We’ve been diligently preparing bottom ten annual lists since 2007, even though it’s distasteful, because if we don’t do it nobody else is likely to, and these abominable decisions deserve to be called out for what they are. While we know that a late-breaking holiday horror, such as T.H. Goodbye to all that in CPAP.

article thumbnail

50-State Survey of State Court Decisions Supporting Expert-Related Judicial Gatekeeping

Drug & Device Law

We think that they can, and for a state (like Pennsylvania and a number of others) that still follows the “ Frye ” standard looking to the “general acceptance” of expert testimony as the touchstone to admissibility, a Rule 702 state-law equivalent might look something like this: Rule 702. E.g. , Walsh v. BASF Corp. , 3d 446, 461 (Pa.

article thumbnail

The FDA and Feasible Alternative Designs

Drug & Device Law

14, 2015) (claimed alternative could not be considered for plaintiffs who “had their surgeries prior to the commercial availability of” the claimed alternative because it “was not approved by the Food and Drug Administration until June 2007 and was not commercially available until late” that year). Baksic relied on Pizzitola v. Ethicon, Inc.

FDA 59
article thumbnail

Unimpressed Learned Intermediaries Defeat Warning Causation

Drug & Device Law

The prescriber’s] testimony, however, does not establish that he would have altered his prescribing conduct. That oncologists prescribing lifesaving standard-of-care treatment in the face of “aggressive cancer” are not impressed by a risk of – permanent hair loss – is not surprising. at *3 (emphasis original). 2d 806, 817 (5th Cir.